Calotatug ginistinag
Calotatug ginistinag (XMT-2056) is an antibody-drug conjugate targeting HER2, with an effective payload connected via a linker (LP, HY-148067) to a STING agonist (STING agonist-20, HY-148068), and has potential immune activation and anticancer activity[1].
Product Specifications
CAS Number
2847102-44-5
Product Name Alternative
XMT-2056
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; EGFR; STING
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related; Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/calotatug-ginistinag.html
Purity
95.94
Smiles
[Calotatugginistinag]
References & Citations
[1]Duvall J R, et al. XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab[J]. Cancer Res, 2022, 82 (12_Supplement) : 3503-3503.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
Phase 1
Isoform
ErbB2/HER2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC940304-100 1x 100 µL
CD106 / VCAM1 (B-K9), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC940040-100 1x 100 µL
CD35 / CR1 (E11), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470050-100 1x 100 µL
IgA Secretory Component (SC05), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 